Summit Therapeutics (SUMM)

Company name:Summit Therapeutics Plc
EPIC:SUMMTrading Currency:GBX
Market Sector:AIMPISIN:GB00BN40HZ01
Market Segment:ASX1Share Type:DE
WWW Address:Description:ORD 1P
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 22.25 images.advfn.com/imagesnew/2/gb/dot 0.0 [0.00] 21.00 23.50 22.25 22.25 22.25 -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 35.71 160.49 -0.01 9.12 - 2.44 - 34.00 - 17.50

Summit Therapeutics Key Figures

(at previous day's close)
Market Cap.35.71m
Shares In Issue160.49m
Prev. Close22.25
PE Ratio2.44 
Dividend Yield-%
EPS - basic9.12p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-16.73p
Return On Equity (ROE)17.69%
Operating Margin11.70%
PEG Factor0.01 
EPS Growth Rate180.00%
Dividends PS Growth Rate-%
Net Debt-9.65m
Gross Gearing28.82%
Quick Assets46.83m
Net Working Capital33.94m
Intangibles / Fixed Assets95.27%
Turnover PS26.86p
Pre-Tax Profit PS3.14p
Retained Profit PS4.70p
Cash PS16.77p
Net Cash PS8.74p
Net Tangible Asset Value PS *18.81p
Net Asset Value PS26.56p
Spread2.50 (10.64%) 

Summit Therapeutics Balance Sheet

SUMM:Liabilities+EQSUMM:Assets

Share Price Performance

Sample Period HighLow
1 week23.0022.00
4 weeks24.0021.75
12 weeks30.0020.00
1 year34.0017.50

Share Price Chart (5 years)

Summit Therapeutics Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week22.000.251.1422.000.0122.06
4 weeks23.75-1.50-6.3221.750.0323.02
12 weeks22.000.251.1420.000.0924.91
26 weeks23.00-0.75-3.2618.500.0823.73
1 year20.002.2511.2517.500.1023.63
3 years170.00-147.75-86.9117.500.1070.65
5 years117.50-95.25-81.0617.500.0995.65

Summit Therapeutics Key Management Ratios

Summit Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio2.44 
Tobin's Q Ratio 0.46 
Tobin's Q Ratio (excl. intangibles)0.63 
Dividend Yield-%
Market-to-Book Ratio0.84 
Price-to-Pre-Tax Profit PS7.08 
Price-to-Retained Profit PS4.73 
Price-to-Cash Flow PS-1.33 
Price-to-Sales PS0.83 
Price-to-Net Tangible Asset Value PS1.18 
Price-to-Cash PS1.33 
Net Working Capital PS21.15 
Price Pct to Working Capital PS1.05%
Earnings Yield40.99%
Average PE1.79 
Years in average1 
PE to PE average136.17%

Summit Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio9.29%
Debt-to-Equity Ratio0.10 
Debt-to-Equity Ratio (excl. Intgbl)0.14 
Debt-to-Equity Market Value0.12 
Net Gearing-16.12%
Net Gearing (excl. Intangibles)-20.35%
Gross Gearing28.82%
Gross Gearing (excl. Intangibles)36.38%
Gearing Under 1 Year21.53%
Gearing Under 1 Year (excl. Intgbl)27.18%
Assets/Equity1.40 
Cash/Equity63.13 
(Liquidity Ratios)
Net Working Capital to Total Assets56.66%
Current Ratio3.63 
Quick Ratio (Acid Test)3.63 
Liquidity Ratio2.09 
Cash & Equiv/Current Assets57.47%
(Solvency Ratios)
Enterprise Value13.16m
CFO/Sales-0.62 
CFO/Attributable Profit- 
CFO/Assets-0.45 
CFO/Debt-1.56 
Total Debt/Equity Market Value0.48 
Total Debt/Sales0.40 
Total Debt/Pre-Tax Profit3.42 
Total Debt17.26m
Total Debt/Net Current Assets0.51%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs7 
Beta (60-Mnth)Beta (36-Mnth)
-0.00770.1595

Summit Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)10.73%
Return On Assets (ROA)9.73%
Net Profit Margin17.50%
Assets Turnover0.56 
Return On Equity (ROE)17.69%
Return On Investment (ROI)13.55%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio21.58%
Net Income Of Revenues17.50%
(Asset Utilisation Multiples)
Shareholders Equity Turnover1.23 
Fixed Assets Turnover2.02 
Current Assets Turnover0.77 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales1.80 
Debtors-to-Sales56.27%
Debt Collection Period205.38Days

Summit Therapeutics Dividends

Sorry No Data Available

Summit Therapeutics Fundamentals

 31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
turnover2.06100.00%2.90100.00%36.07100.00%56.50100.00%m
pre tax profit-28.58-1,388.48%-32.35-1,116.04%-15.46-42.85%6.6111.70%m
attributable profit-24.24-1,177.75%-26.86-926.53%-10.12-28.05%9.8917.50%m
retained profit-24.24-1,177.75%-26.86-926.53%-10.12-28.05%9.8917.50%m
eps - basic-41.00 -44.00 -15.00 12.00 
eps - diluted-41.00 -44.00 -15.00 12.00 
dividends per share- - - - 

Summit Therapeutics Balance Sheet

 31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
SUMM:Liabilities+EQSUMM:AssetsSUMM:Liabilities+EQSUMM:AssetsSUMM:Liabilities+EQSUMM:AssetsSUMM:Liabilities+EQSUMM:Assets
 31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
ASSETS
fixed assets fixed assets0.120.33%0.150.31%1.151.50%0.811.03%m
intangibles intangibles5.8716.50%5.2011.00%24.5031.99%16.3120.78%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks--%--%--%--%m
debtors debtors6.4618.15%6.6414.03%22.4029.26%26.1133.25%m
cash & securities cash & securities23.1365.02%35.3274.66%28.5337.25%35.2844.94%m
TOTAL35.57100%47.30100%76.57100%78.50100%m
LIABILITIES
creditors - short creditors - short4.5512.79%13.7128.99%26.8835.11%16.9021.53%m
creditors - long creditors - long1.042.94%37.9980.30%35.6846.59%5.727.29%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL5.5915.72%51.70109.29%62.5681.70%22.6228.82%m
EQUITY
ord cap, reserves ord cap, reserves29.9784.28%-4.40-9.29%14.0118.30%55.8871.18%m
prefs, minorities prefs, minorities--%--%--%--%m
TOTAL29.9784.28%-4.40-9.29%14.0118.30%55.8871.18%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Summit Therapeutics Cash Flow Statement

31 Jan 2016 (USD)31 Jan 2017 (USD)31 Jan 2018 (USD)31 Jan 2019 (USD)
Operating CF-24.3715.28-20.84-35.20m
Pre-Financing CF-24.4215.18-28.28-35.61m
Retained CF6.9715.70-8.558.31m

Summit Therapeutics Brokers

NameActivityTypeMnemonicCode
Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Panmure Gordon (UK) LimitedMarket Maker(MMF)Broker/DealerPMURPMURGB2L
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
LSE
SUMM
Summit The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191206 08:17:14